Dexamethasone controlled release - Taiwan Liposome Company

Drug Profile

Dexamethasone controlled release - Taiwan Liposome Company

Alternative Names: ProDex; TLC-399

Latest Information Update: 13 Jul 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Taiwan Liposome Company
  • Class Anti-inflammatories; Antiemetics; Antineoplastics; Fluorinated steroids; Glucocorticoids; Pregnadienetriols; Small molecules
  • Mechanism of Action Glucocorticoid receptor agonists; Immunosuppressants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase II Retinal oedema

Most Recent Events

  • 11 Jul 2017 Taiwan Liposomal Company receives Australian patent covering dexamethasone controlled-release
  • 03 Apr 2017 Taiwan Liposome plans a phase II trial for Retinal oedema in USA (NCT03093701)
  • 01 Apr 2017 Phase-II clinical trials in Retinal oedema in USA (Intravitreous) (NCT03093701)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top